{"id":598,"date":"2026-04-12T15:32:34","date_gmt":"2026-04-12T15:32:34","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=598"},"modified":"2026-08-30T03:53:25","modified_gmt":"2026-08-30T03:53:25","slug":"lucipac-pacritinib-100-mgx120-capsules","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/ru\/product\/lucipac-pacritinib-100-mgx120-capsules\/","title":{"rendered":"LuciPac"},"content":{"rendered":"<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">HIGHLIGHTS OF PRESCRIBING INFORMATION <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">These highlights do not include all the information needed to use LuciP<\/span><span style=\"font-size: 14px;\">ac<\/span><span style=\"font-size: 14px;\">&nbsp;safely and effectively. See full prescribing information for LuciP<\/span><span style=\"font-size: 14px;\">ac<\/span><span style=\"font-size: 14px;\">.<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"color: rgb(88, 88, 88); font-size: 17px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">INDICATIONS AND USAGE<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">LuciPac is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50<\/span><span style=\"font-size: 14px;\">\u00d7<\/span><span style=\"font-size: 14px;\">10<\/span><sup><span style=\"font-size: 14px; vertical-align: super;\">9<\/span><\/sup><span style=\"font-size: 14px;\">\/L . <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">DOSAGE AND ADMINISTRATION<\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span> <span style=\"font-size: 14px;\">&nbsp;Recommended dosage is 200 mg orally twice daily. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span> <span style=\"font-size: 14px;\">&nbsp;May be taken with or without<\/span><span style=\"font-size: 14px;\">&nbsp;food.<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">DOSAGE FORMS AND STRENGTHS <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">Capsules: <\/span><span style=\"font-size: 14px;\">100<\/span><span style=\"font-size: 14px;\">&nbsp;mg\u00d7<\/span><span style=\"font-size: 14px;\">120<\/span><span style=\"font-size: 14px;\">&nbsp;capsules<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">CONTRAINDICATIONS <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">Concomitant use of strong CYP3A4 inhibitors or inducers<\/span><span style=\"font-size: 14px;\">.<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">WARNINGS AND PRECAUTIONS <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Hemorrhage: Avoid use in patients with active bleeding and hold LuciPac prior to any planned surgical procedures. May require dose interruption, dose reduction or permanent discontinuation depending on severity. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Diarrhea: Manage significant diarrhea with anti-diarrheals, dose reduction, or dose interruption. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Thrombocytopenia: Manage by dose reduction or interruption. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Prolonged QT Interval: Avoid use in patients with baseline QTc &gt;480 msec. Interrupt and reduce LuciPac dosage in patients who have a QTcF &gt;500 msec. Correct hypokalemia prior to and during LuciPac administration. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Major Adverse Cardiac Events (MACE): Risk may be increased in current\/past smokers and patients with other cardiovascular risk factors. Monitor for signs, evaluate and treat promptly. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Thrombosis: Including deep venous thrombosis, pulmonary embolism, and arterial thrombosis may occur. Monitor for signs, evaluate and treat promptly. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Secondary Malignancies: Lymphoma and other malignancies may occur. Past\/current smokers may be at increased risk. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">\u2022<\/span><span style=\"font-size: 14px;\">&nbsp;<\/span><span style=\"font-size: 14px;\">Risk of Infection: Delay starting LuciPac until active serious infections have resolved. Observe for signs and symptoms of infection and manage promptly<\/span><span style=\"font-size: 14px;\">.<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">ADVERSE REACTIONS <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">The most common (\u226520% of patients) adverse reactions are diarrhea, <\/span><span style=\"font-size: 14px;\">thrombocytopenia, nausea, anemia, and peripheral edem<\/span><span style=\"font-size: 14px;\">a.<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">DRUG INTERACTIONS <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">Avoid use with moderate CYP3A4 inhibitors or inducers<\/span><span style=\"font-size: 14px;\">.<\/span><\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">Coadministration of LuciPac can alter the concentration of drugs that are Pgp, BCRP, or OCT1 substrates. Avoid use with sensitive substra<\/span><span style=\"font-size: 14px;\">tes.<\/span><\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">USE IN SPECIFIC POPULATIONS <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">Lactation: Advise not to breastfeed. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">Hepatic Impairment: Avoid use in moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C) . <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">Renal Impairment: Avoid use in patients with eGFR &lt;30 mL\/mi<\/span><span style=\"font-size: 14px;\">n.<\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size: 14px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><strong><span style=\"font-size: 14px;\">Storage <\/span><\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\"><span style=\"font-size: 14px;\">Store at 20<\/span><span style=\"font-size: 14px;\">\u2103<\/span><span style=\"font-size: 14px;\">&nbsp;to 25<\/span><span style=\"font-size: 14px;\">\u2103<\/span><span style=\"font-size: 14px;\">&nbsp;(68<\/span><span style=\"font-size: 14px;\">\u2109<\/span><span style=\"font-size: 14px;\">&nbsp;to 77<\/span><span style=\"font-size: 14px;\">\u2109<\/span><span style=\"font-size: 14px;\">), excursions permitted between 15<\/span><span style=\"font-size: 14px;\">\u2103<\/span><span style=\"font-size: 14px;\">&nbsp;and 30<\/span><span style=\"font-size: 14px;\">\u2103<\/span><span style=\"font-size: 14px;\">&nbsp;(59<\/span><span style=\"font-size: 14px;\">\u2109<\/span><span style=\"font-size: 14px;\">&nbsp;and 86<\/span><span style=\"font-size: 14px;\">\u2109<\/span><span style=\"font-size: 14px;\">) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"color: rgb(88, 88, 88); font-size: 17px;font-family:\u5fae\u8f6f\u96c5\u9ed1, Microsoft YaHei\">&nbsp;<\/span><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciPac is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosi<\/p>","protected":false},"featured_media":1800,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[21],"product_tag":[],"class_list":["post-598","product","type-product","status-publish","has-post-thumbnail","product_cat-blood-disease","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product\/598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/comments?post=598"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/media\/1800"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/media?parent=598"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product_brand?post=598"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product_cat?post=598"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ru\/wp-json\/wp\/v2\/product_tag?post=598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}